Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 NY-ESO-1 TCR-transduced T lymphocytes in refractory ATLL after allo-HSCT
jRCT2080223774Phase 1Completed
- Sponsor
- Dokkyo Medical University, Tokyo University. Nagoya City University, Mie University, Osaka International Cancer Institute, Kyushu University, Nagasaki University, Kagoshima University, Imamura General Hospital
- Start
- Jan 2018
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TBI-1301-A in adult T-cell leukemia-lymphoma (ATLL) (5 cohorts), sponsored by Dokkyo Medical University, Tokyo University. Nagoya City University, Mie University, Osaka International Cancer Institute, Kyushu University, Nagasaki University, Kagoshima University, Imamura General Hospital. Primary endpoints: Primary safety and tolerability of TBI-1301-A and Feasibility of manufacturing and administering TBI-1301-A. Started Jan 2018; status: completed.
02
Drugs
TBI-1301-A
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCT2080223774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223774.